IL13RA2 and glioblastoma: Currently, a phase I clinical trial (NCT04003649) is recruiting patients to evaluate the efficacy of IL13Rα2 CAR-T cells alone or in combination with nivolumab and ipilimumab for the treatment of relapsed or refractory GBM.